FDA Updates COVID Shot Labels Over Rare Heart Risk
The FDA has required Pfizer and Moderna to expand their vaccine labels to include updated warnings about myocarditis, a rare heart inflammation linked to COVID‑19 shots. The updated warning reflects data from the 2023–2024 vaccine formulations.
The updated labels now note about 8 cases of myocarditis per 1 million people aged 6 months to 64 years. They also specify that male teenagers and young adults (ages 12–24) are most commonly affected—widening the previously noted age group of 12–17.
Early signs appeared in 2021, but the new data reflects more recent vaccine versions. The FDA asked manufacturers to update the label in April, following negotiations.
Interestingly, the CDC’s vaccine advisory panel did not detect increased myocarditis cases from these vaccines since 2022, noting most cases are mild and less severe than those from COVID‑19 infection.
This update comes amid policy shifts led by Health Secretary Robert F. Kennedy Jr., including changes to the CDC advisory panel and guidance that limits COVID shots to older adults and high-risk individuals.
Critics argue labeling alone isn’t enough. Dr. Robert Morris from the University of Washington says:
“We should be investigating who is prone to myocarditis to see if we can predict and mitigate that risk.”
While heart inflammation following COVID‑19 vaccination remains rare and generally mild, the FDA’s label update aims for transparency. Health experts say continued study of risk factors is essential to ensure vaccine safety and informed decision‑making.
